Note 5 - Collaboration Agreements (Details Textual) ¥ in Billions	1 Months Ended	12 Months Ended
	Nov. 30, 2020 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2021 CNY (¥)
Revenue from Contract with Customer, Including Assessed Tax		$ 0	$ 0
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member]
Collaboration Agreement,, Maximum Regulatory Development Milestones to be Received				$ 100,099,000	¥ 0.7
Collaboration Agreement, Maximum Commercial Milestones to be Received				57,199,000	0.4
Revenue from Contract with Customer, Excluding Assessed Tax		0	0
Revenues	$ 780,000	3,000
Revenue from Contract with Customer, Including Assessed Tax		$ 2,001,000	$ 2,001,000
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member] | Maximum [Member]
Collaborative Arrangement, Equity Investment	$ 10,000,000
Jiangsu Hengrui Pharmaceuticals Co., Ltd. [Member] | Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) [Member]
Collaboration Agreement, Upfront Cash Payment				$ 28,600,000	¥ 0.2